Trials / Unknown
UnknownNCT06142175
Relmacabtagene Autoleucel in Patients With LBCL
A Real World Study of Treatment of Relmacabtagene Autoleucel in Relapsed or Refractory Large B-Cell Lymphoma
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Shanghai Ming Ju Biotechnology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of Relmacabtagene autoleucel for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) in real-world
Detailed description
This is a post-marketing, multicenter, observational real-world study, including prospective and retrospective studies. The purpose of this study is to collect efficacy and safety data over a 6-month period following treatment of adult patients with r/r LBCL with Relmacabtagene autoleucel. The treating physicians in the study will determine the most appropriate diagnostic and therapeutic regimen for their patients based on clinical practice.There will be no therapeutic intervention as a result of this study. There will be no subgroups of any kind in this study, and subgroup analyses will be performed based on the actual data collected during the analysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Relmacabtagene Autoleucel | A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells |
Timeline
- Start date
- 2022-12-28
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
- First posted
- 2023-11-21
- Last updated
- 2024-03-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06142175. Inclusion in this directory is not an endorsement.